Impact of loss of NF-kappaB1, NF-kappaB2 or c-REL on SLE-like autoimmune disease and lymphadenopathy in Fas mutant mice
Details
Publication Year 2016-01,Volume 94,Issue #1,Page 66-78
Journal Title
Immunol Cell Biol
Publication Type
Journal Article
Abstract
Defects in apoptosis can cause autoimmune disease. Loss-of-function mutations in the 'death receptor' FAS impair the deletion of autoreactive lymphocytes in the periphery, leading to progressive lymphadenopathy and systemic lupus erythematosus-like autoimmune disease in mice (Faslpr/lpr (mice homozygous for the lymphoproliferation inducing spontaneous mutation)) and humans. The REL/nuclear factor-kappaB (NF-kappaB) transcription factors regulate a broad range of immune effector functions and are also implicated in various autoimmune diseases. We generated compound mutant mice to investigate the individual functions of the NF-kappaB family members NF-kappaB1, NF-kappaB2 and c-REL in the various autoimmune pathologies of Faslpr/lpr mutant mice. We show that loss of each of these transcription factors resulted in amelioration of many classical features of autoimmune disease, including hypergammaglobulinaemia, anti-nuclear autoantibodies and autoantibodies against tissue-specific antigens. Remarkably, only c-REL deficiency substantially reduced immune complex-mediated glomerulonephritis and extended the lifespan of Faslpr/lpr mice. Interestingly, compared with the Faslpr/lpr animals, Faslpr/lprnfkb2-/- mice presented with a dramatic acceleration and augmentation of lymphadenopathy that was accompanied by severe lung pathology due to extensive lymphocytic infiltration. The Faslpr/lprnfkb1-/- mice exhibited the combined pathologies caused by defects in FAS-mediated apoptosis and premature ageing due to loss of NF-kappaB1. These findings demonstrate that different NF-kappaB family members exert distinct roles in the development of the diverse autoimmune and lymphoproliferative pathologies that arise in Faslpr/lpr mice, and suggest that pharmacological targeting of c-REL should be considered as a strategy for therapeutic intervention in autoimmune diseases.Immunology and Cell Biology advance online publication, 14 July 2015; doi:10.1038/icb.2015.66.
Publisher
NPG
Research Division(s)
Molecular Genetics Of Cancer
PubMed ID
26084385
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2015-11-11 12:04:04
Last Modified: 2016-01-13 09:52:38
An error has occurred. This application may no longer respond until reloaded. Reload 🗙